Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Chimpanzee Adenovirus HIV-1 Vaccines (AdC6/AdC7) and CH505TF gp120 Boost in Healthy Adults
NCT05182125Phase 1Completed
- Sponsor
- HIV Vaccine Trials Network
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Viral Vector Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised trial of AdC6-HIVgp140, AdC7-HIVgp140 and CH505TF gp120 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by HIV Vaccine Trials Network. Primary endpoints: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration and 5 more. Started Nov 2021; status: completed.
02
Drugs
AdC6-HIVgp140AdC7-HIVgp140CH505TF gp120
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05182125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182125.